Neuron | Inhibitor | Substrate | 0–1 h (% control rate) | 1–2 h (% control rate) |
---|---|---|---|---|
DRG | Cycloheximide | Laminin | 98 ± 9 | 54 ± 12 |
Anisomycin | Laminin | 88 ± 14 | 39 ± 11 | |
Puromycin | Laminin | 75 ± 10 | 26 ± 14 | |
DRG | Cycloheximide | L1 | 76 ± 15 | 34 ± 12 |
Anisomycin | L1 | 96 ± 13 | 25 ± 9 | |
Retina | Cycloheximide | L1 | 83 ± 11 | 59 ± 9 |
Anisomycin | L1 | 84 ± 8 | 67 ± 9 |
E7 DRG or temporal retina explants were cultured in laminin- or L1-coated wells in F-12, B27 with 10 ng/ml NGF added to DRG cultures. After 24 h 20 μm CHI, anisomycin or puromycin, or the drug vehicle was added to a well of a dish on a warm microscope stage, and video images were collected at 2–5 min intervals for 2 h or more. Axon elongation rates were determined using Metamorph software to measure axon elongation at 5–10 min intervals. Average ± SEM axon elongation in drug-treated cultures is expressed as percentage of the elongation rate in vehicle-treated control cultures.